Clinical-Microbiomics A/S: Financial statements 2019
CVR: 37230634
Source: annual report 2019, Danish Business Authority
01/01/2019 – 31/12/2019
Clinical-Microbiomics A/S (CVR 37230634) has filed annual accounts for 2019. In 2019, the company reported a gross profit of DKK 13,163,250 and a net result of DKK 106,977 compared with DKK -482,947 the year before. That is an increase of 54.7% compared with the year before. Equity in the 2019 report amounted to DKK -4,146,581. The company had 16 employees in the financial year.
- Gross Profit
- DKK 13,163,250
- Profit/Loss
- DKK 106,977
- Equity
- DKK -4,146,581
- Total Assets
- DKK 11,538,520
- Employees
- 16
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2019 | - | 13.2 mio. | 107 t. | -4.1 mio. | 16 |
| 2018 | - | 8.5 mio. | -483 t. | -4.3 mio. | 12 |
| 2017 | - | 1.4 mio. | -4.4 mio. | -3.8 mio. | 9 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2019
As of November 1, 2019, Morten Asser Karsdal has joined the board of directors of Clinical-Microbiomics A/S.
Clinical-Microbiomics A/S has published its annual report for 2018. Gross profit came to DKK 8,507,396, and the net result was DKK -482,947.
About Clinical-Microbiomics A/S
Clinical-Microbiomics A/S is a Danish company of the type Aktieselskab based in København Ø, founded in 2015. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named Clinical-Microbiomics ApS. The management consists of Anders Christian Neto de Sousa Grøn. The board consists of Manoj Nirmal Dadlani (chair), Bruce Harvey Grant, Caroline Popper and Isabelle Valerie de Cremoux. The company's owners include MANJIN ApS, VENDLER ApS and Health For Life Capital II Prima S.C.A. RAIF. The company has 32 employees (2026). In 2025, the company reported a gross profit of EUR 2,831,000 and a net result of EUR -2,586,000 compared with EUR -4,328,000 the year before. Equity in the 2025 report amounted to EUR 85,447,000.